Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Aug 1:6:30800.
doi: 10.1038/srep30800.

A Catalogue of Altered Salivary Proteins Secondary to Invasive Ductal Carcinoma: A Novel In Vivo Paradigm to Assess Breast Cancer Progression

Charles F Streckfus  1 , Lenora Bigler  1
Affiliations
Clinical Trial

A Catalogue of Altered Salivary Proteins Secondary to Invasive Ductal Carcinoma: A Novel In Vivo Paradigm to Assess Breast Cancer Progression

Charles F Streckfus et al. Sci Rep. .

Abstract

The objective of this manuscript is to introduce a catalogue of salivary proteins that are altered secondary to carcinoma of the breast. The catalogue of salivary proteins is a compilation of twenty years of research by the authors and consists of 233 high and low abundant proteins which have been identified by LC-MS/MS mass spectrometry, 2D-gel analysis and by enzyme-linked immunosorbent assay. The body of research suggests that saliva is a fluid suffused with solubilized by-products of oncogenic expression and that these proteins may be useful in the study of breast cancer progress, treatment efficacy and the tailoring of individualized patient care.

PubMed Disclaimer

Figures

Figure 1
Figure 1. The figure represents the number and percentage of proteins as classified by function.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kiberstis P. & Roberts L. A race still unfinished. Science 343, 1451 (2014). - PubMed
    1. Eccles S. A. et al.. Clinical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. R92 (2013). - PMC - PubMed
    1. Kulkarni Y. M., Suarez V. & Klinke D. J. Inferring predominant pathways in cellular models of breast cancer using limited sample proteomic profiling. BMC Cancer 10, 291–303 (2010). - PMC - PubMed
    1. Vargo-Gogola T. & Rosen J. M. Modelling breast cancer: one size does not fit all. Nature Reviews Cancer 7, 659–672 (2007). - PubMed
    1. Tordai A. et al.. Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Res. 10, R37 (2008). - PMC - PubMed

Publication types

MeSH terms

Substances